(Q43684793)

25 November 2017

title

Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr. (English)

1 reference

25 November 2017

main subject

fluticasone propionate

1 reference

beclomethasone dipropionate

inferred from title

1 reference

Lorentzen KA

1

1 reference

25 November 2017

Van Helmond JL

2

1 reference

25 November 2017

Bauer K

3

1 reference

25 November 2017

Langaker KE

4

1 reference

25 November 2017

Bonifazi F

5

1 reference

25 November 2017

Harris TA

6

1 reference

25 November 2017

publication date

1 November 1996

1 reference

25 November 2017

1 reference

25 November 2017

volume

90

1 reference

25 November 2017

issue

10

1 reference

25 November 2017

page(s)

609-617

1 reference

Guidelines on the management of asthma. Statement by the British Thoracic Society, the Brit. Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal Colle

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Inhaled corticosteroids: benefits and risks

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

The human pharmacology of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Systemic effects of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990019-0

7 January 2021

10.1016/S0954-6111(96)90019-0

Identifiers

DOI

1 reference

25 November 2017

1 reference